Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | IKBKB | O14920 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5388755 | 0.80 | KIF11 (0.49) | MEN1KMT2AMAPTMCOLN3NPC1 | |
| SCHEMBL27941188 | 0.80 | MAPT (0.35) | TSHRMAPTMCOLN3NPC1RAB9A | |
| SCHEMBL5382568 | 0.80 | MAPT (0.35) | L3MBTL1TSHRMAPTMCOLN3 | |
| SCHEMBL183361 | 0.79 | MAPK10 (0.31) | KDM4EHSD17B10 | |
| SCHEMBL2540701 | 0.78 | MAPT (0.34) | ALDH1A1KDM4EMAPTMCOLN3NPC1 | |
| SCHEMBL5387252 | 0.77 | MAPT (0.33) | MAPTMCOLN3 | |
| SCHEMBL171307 | 0.76 | ALDH1A1 (0.54) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL5478680 | 0.76 | — | — | |
| SCHEMBL5487767 | 0.76 | — | — | |
| SCHEMBL687171 | 0.75 | ALDH1A1 (0.40) | MEN1KMT2ALMNAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115974844-A | 3,4,5-trimethoxyphenyl derivative and application thereof | 广东省科学院动物研究所 | 2023-04-18 | — | — | CN | claimed |
| CN-101490016-A | 2,4-substituted quinazolines as lipid kinase inhibitors | NOVARTIS AG (CH) | 2009-07-22 | — | — | CN | claimed |
| US-7507732-B2 | Cyclopentapyridine and tetrahydroquinoline derivatives | PFIZER INC. (US) | 2009-03-24 | — | — | US | claimed |
| CN-115974844-A | 3,4,5-trimethoxyphenyl derivative and application thereof | 广东省科学院动物研究所 | 2023-04-18 | — | — | CN | disclosed |
| CN-110300590-A | TYK2 inhibitor and application thereof | 林伯士拉克许米公司 | 2019-10-01 | — | — | CN | disclosed |
| EP-2145884-B1 | INDOLEDIONE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-8106086-B2 | Indoledione derivative | MSD K.K. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-8044070-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2011-10-25 | — | — | US | disclosed |
| CN-101151249-B | Cyclopentapyridine and tetrahydroquinoline derivatives | PFIZER PRODUCTS INC. (US) | 2011-04-06 | — | — | CN | disclosed |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | MSD K.K. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-20100056597-A1 | INDOLEDIONE DERIVATIVE | MSD K.K. (JP) | 2010-03-04 | — | — | US | disclosed |
| CN-1439018-A | 9alpha-chloro-6alpha-fluoro-17alpha-hydroxy-16-methyl-17-beta-methoxy carbonyl-androst-1, 4-dienes esterified in position 17 alpha by a cyclic acyl group | NOVARTIS AG (CH) | 2003-08-27 | — | — | CN | disclosed |
| US-20030105123-A1 | For therapy of respiratory system disorders | ALTANA PHARMA AG (DE) | 2003-06-05 | — | — | US | disclosed |
| WO-2003020721-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
| EP-1250325-A1 | PHENANTHRIDINE-N-OXIDES | ALTANA Pharma AG (DE) | 2002-10-23 | — | — | EP | disclosed |
| EP-0889886-B1 | NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION | ALTANA PHARMA AG (DE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001051470-A1 | PHENANTHRIDINE-N-OXIDES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-07-19 | — | — | WO | disclosed |
| US-6127378-A | A PHOSPHODIESTERASE ENZYME INHIBITOR AS BRONCHIAL THERAPEUTICS, AN ANTIINFLAMMATORY AGENT TREATING ASTHMA PROPHYLAXIS, SKIN DISORDERS, INTESTINE DISORDERS, EYE DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, JOINTS DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-10-03 | — | — | US | disclosed |
| EP-0889886-A1 | NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1999-01-13 | — | — | EP | disclosed |
| WO-1997035854-A1 | NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105123-A1 | For therapy of respiratory system disorders | CHRM3, CYP11B1, CYP11B2 | MEN1 3969/4885KMT2A 3871/4885LMNA 2520/4885 |
| US-20100056597-A1 | INDOLEDIONE DERIVATIVE | LIPE, IDO1, ADRA1A | MEN1 2086/4885KMT2A 776/4885LMNA 1165/4885 |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | HRH3, HRH4, HRH2 | MEN1 1602/4885KMT2A 552/4885LMNA 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.